Get the Stockscreener App
11.00
0.18%
-0.02
Immucell Corp stock is traded at $11.00, with a volume of 9,704.
It is down -0.18% in the last 24 hours and up +6.38% over the past month.
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.
See More
Previous Close:
$11.02
Open:
$10.95
24h Volume:
9,704
Relative Volume:
0.33
Market Cap:
$99.51M
Revenue:
$29.93M
Net Income/Loss:
$-545.30K
P/E Ratio:
-182.72
EPS:
-0.0602
Net Cash Flow:
$3.38M
1W Performance:
-1.87%
1M Performance:
+6.38%
6M Performance:
+76.28%
1Y Performance:
+79.15%
1-Day Range:
$10.76
$11.03
1-Week Range:
$10.50
$11.38
52-Week Range:
$4.52
$12.10
Immucell Corp Stock (ICCC) Company Profile
Name
Immucell Corp
Sector
Industry
Phone
(207) 878-2770
Address
56 EVERGREEN DR, PORTLAND, ME
Compare ICCC vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ICCC
Immucell Corp
|
11.00 | 100.69M | 29.93M | -545.30K | 3.38M | -0.0602 |
VRTX
Vertex Pharmaceuticals Inc
|
496.07 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.36 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
865.04 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.15 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
348.27 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Immucell Corp Stock (ICCC) Latest News
ImmuCell Corp (ICCC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ImmuCell Corp (ICCC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ImmuCell Corp (ICCC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ICCC|ImmuCell Corp|Price:11.135|Chg%:+0.105 - TradingKey
ImmuCell Corp (ICCC) Cash Flow - TradingKey
ImmuCell Corp (ICCC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ImmuCell Corp (ICCC) Institutional Confidence - TradingKey
ImmuCell Corp (ICCC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TradingKey - TradingKey
ImmuCell Corp (ICCC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
MSN Money - MSN
Biotech Stocks At 52-Week Highs: AMWL, CUE, ICCC, SRRK, FTH - RTTNews
ImmuCell Posts Strong Preliminary Q2 Sales on U.S. Demand - Yahoo Finance
ImmuCell Corporation Files Form 8-K: Key Financial Data and Company Information for July 2026 - Minichart
ImmuCell reports 11.5% sales increase in second quarter - Investing.com
ImmuCell (ICCC) Reports Significant Growth in Quarterly Sales - GuruFocus
ImmuCell Announces a 12% Increase in Product Sales in Q2 of 2026 and a 21% Increase in the First Six Months of 2026, Based on Preliminary, Unaudited Sales Results - The Manila Times
ImmuCell reports Q2 product sales up 11.5% to $7.2M; six‑month sales up 20.9% to $17.5M - TradingView
ImmuCell (ICCC) Q2 2026 sales hit $7.2M as six-month revenue climbs 20.9% - Stock Titan
ImmuCell sales jump 12% in Q2 as U.S. demand lifts calf products - Stock Titan
ImmuCell adds Jacee Lancaster to Commercial Team - Feedstuffs
ImmuCell Corporation (ICCC) Gains 1.39% as Stock Approaches Key Resistance at $10.70Inverse ETF Flow - dars.gov.et
ICCC's valuation remains premium: Is it worth overpaying for? - MSN
The Zacks Analyst Blog Highlights JPMorgan, Novartis, Qualcomm, Genie and ImmuCell - Yahoo Finance
ImmuCell CEO buys $75,960 in common stock - Investing.com UK
Insider Buying: te Boekhorst Paul Francis Olivier Acquires Additional Shares of ImmuCell Corp (ICCC) - GuruFocus
Form 4 ImmuCell Corporation For: 22 June By Investing.com - Investing.com Nigeria
ImmuCell CEO buys $75,960 in common stock By Investing.com - Investing.com Canada
ImmuCell (ICCC) CEO increases stake with 8,000-share open-market buy - Stock Titan
ICCC's Valuation Remains Premium: Is it Worth Overpaying for? - The Globe and Mail
ImmuCell shareholders approve director elections and key proposals at annual meeting - Investing.com
ImmuCell (NASDAQ: ICCC) investors approve directors, pay plan, auditor - Stock Titan
ImmuCell Corp (ICCC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ImmuCell Corp (ICCC) Valuation: PE, PB & Fair Value Analysis - TradingKey
ImmuCell (NASDAQ: ICCC) approves $3.5M First Defense expansion plan - Stock Titan
Jonathan Ocampo joins ImmuCell Commercial Team - Feedstuffs
ICCC Q1 2026 Earnings: EPS of $0.21 Reported Without Revenue Disclosure; Stock Declines 3% - DonanımHaber
ICCC Technical Analysis | Trend, Signals & Chart Patterns | IMMUCELL CORP (NASDAQ:ICCC) - ChartMill
ImmuCell Corp. Hits New 52-Week High of $10.65, Up 145% - MarketsMojo
ImmuCell Corporation (ICCC) Surges 3.75% to $10.50 as Bulls Test Key ResistanceNews Sentiment - The Legal Advocate
ImmuCell Shares Rose Ahead of Holiday; Tuesday’s Open in Focus - Bez Kabli
ImmuCell Q1 Earnings Rise Y/Y as Sales Climb on Strong Demand - Yahoo Finance
ICCC SEC FilingsImmucell 10-K, 10-Q, 8-K Forms - Stock Titan
ImmuCell Corporation (ICCC) Climbs +10.76% — Resistance at $10.37 in Focus 2026-05-18Median Line - newsline.com
ImmuCell Corporation (NASDAQ:ICCC) Q1 2026 Earnings Call Transcript - Insider Monkey
Immucell Corp Stock (ICCC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immucell Corp Stock (ICCC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BRIGHAM MICHAEL F | Director |
Mar 20 '26 |
Option Exercise |
5.84 |
25,000 |
146,000 |
229,752 |
| te Boekhorst Paul Francis Oliv | President and CEO |
Dec 03 '25 |
Buy |
5.02 |
6,077 |
30,536 |
9,785 |
| te Boekhorst Paul Francis Oliv | President and CEO |
Dec 02 '25 |
Buy |
4.87 |
3,708 |
18,053 |
3,708 |
| Tomsche David Scott | Director |
Nov 25 '25 |
Buy |
4.76 |
1,633 |
7,781 |
4,740 |
| Tomsche David Scott | Director |
Nov 25 '25 |
Buy |
4.76 |
1,633 |
7,773 |
52,720 |
1.84%
0.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):